The recent acquisition of common stock by Mark L. Baum, Chief Executive Officer of Harrow, Inc. (NASDAQ:HROW), represents a notable instance of insider buying activity. On May 14, 2026, Mr. Baum purchased 10,000 shares of the company's common stock, with the total investment reaching $302,000. The price range for these transactions spanned from $30.18 to $30.34 per share.
This substantial insider purchase was reported following a period where HROW stock had declined by 19% over the preceding week. Despite this recent downward trend in the stock, analysis provided by InvestingPro suggests that the company may still be undervalued at current market levels.
The details of Mr. Baum's acquisition show that the shares were acquired at a weighted average price of $30.20 per share. Following this specific transaction, Mark L. Baum's personal holdings in Harrow, Inc.'s common stock increased, bringing his direct ownership total to 2,996,130 shares.
These insider movements occur against a backdrop of recent corporate financial reporting for the broader entity, Harrow Health Inc. In its first-quarter 2026 financial results, the company reported figures that fell short when compared to what market analysts had anticipated.
Specifically, the earnings per share (EPS) was announced at -$0.74. This figure significantly deviated from the expected EPS of -$0.35. Furthermore, revenue totaled $44.2 million, which was below the projected revenue estimate of $52.55 million.
In response to these quarterly outcomes, Cantor Fitzgerald adjusted its financial outlook for Harrow Health shares. The firm revised its price target downward from $91 to $88, while simultaneously maintaining an Overweight rating on the stock. Additionally, Cantor Fitzgerald modified its 2026 revenue forecast for Harrow Health's Vevye product line, lowering the estimate to $146 million, compared to the original projection of $173 million.
These combined recent developments underscore ongoing financial challenges that Harrow Health is encountering in meeting established financial forecasts. Investors are currently dedicating close attention to these updates as they seek to accurately assess the company’s anticipated future performance and trajectory.
For those seeking deeper market insights, InvestingPro offers additional research tools, including 14 ProTips for HROW and a comprehensive Pro Research Report containing expert analysis.